Takeda to host two panel discussions on digital innovation showing promise in advancing treatment of depression at American Psychiatric Association Annual Meeting Innovation Zone

May 15, 2019

Deerfield, IL, May 15, 2019– As part of the American Psychiatric Association (APA) 2019 Annual Meeting Innovation Zone, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) will help answer the question “What’s next in mental health technology?” by hosting two panel discussions. A broad group of mental health experts, including patient advocates, healthcare providers, technology experts, scientists, healthcare systems and payers, will discuss technology and major depressive disorder (MDD), also known as depression.

These panel discussions are timely as May is Mental Health Awareness Month. According to the National Institute of Mental Health, MDD is one of the most common mental health conditions in the United States affecting more than 17 million individuals in 2017 [1].

“It’s important that we partner with a diverse community of medical and scientific experts, leaders in technology, healthcare systems, payers and especially patients, in efforts to pursue innovative ways to advance the treatment of mental illness,” said Louis Mini, M.D., VP of Neuroscience, U.S. Medical Office for Takeda. “Through our partnerships, we’ve seen that digital technology and new digital platforms have the potential to enable us to better support patients and healthcare providers. Takeda is focused on further strengthening our commitment to neuroscience.”

Panel Discussion 1: Sunday, May 19, 9:00 a.m. – 10:00 a.m. PDT

Goal Attainment: Enhanced Shared Decision Making Through Digital Innovation in MDD

Panel will discuss the framework of an approach from a first-of-its-kind study that demonstrated the importance of patients setting personalized treatment goals for MDD. They’ll cover a diverse set of perspectives on the current state of MDD, existing gaps in care, and the potential for technology and innovation to help improve patient outcomes. Examples of goal setting frameworks and initiatives using integrated digital technology will also be shared. 


Panel Discussion 2: Tuesday, May 21, 12:00 noon – 1:00 p.m. PDT

Digital Innovation to Optimize MDD Care: Payer and Provider Perspectives

Panel will discuss the role of innovative digital tools in advancing treatment for MDD with a focus on optimizing success by having alignment between healthcare providers and payers. They’ll explore how the use of technology may improve patient outcomes, and discuss strategies to align payers and providers around use of digital tools to achieve shared goals. 

Both panels will reflect on the learnings from a scientific poster being presented at APA titled A Study to Assess Digitally Enabled Engagement in Major Depressive Disorder.

 

About the Mental Health Innovation Zone

The American Psychiatric Association (APA) is hosting the 2019 Mental Health Innovation Zone, presented by Takeda Pharmaceuticals, U.S.A., a showcase and catalyst for new mental health technologies, as part of its 2019 Annual Meeting in San Francisco. The Innovation Zone is focused on answering the question: "What is next in mental health technology?" It will include lectures, panel discussions, workshops and a "Shark Tank"-style innovation session where attendees can pitch their own product ideas.

See the full Innovation Zone agenda here. More on APA Annual Meeting.

 

Takeda’s Commitment to Neuroscience 

Neuroscience is a core therapeutic area for Takeda. Our mission is to bring innovative medicines to patients suffering from neurologic and psychiatric diseases for whom there are no treatments available. We identify targets either genetically linked with specific neurologic or psychiatric disorders or with high association to the disease pathophysiology, design and operationalize clinical trials in novel ways in an effort to overcome historical challenges, and collaborate with patients, academic institutions, pharmaceutical and biotechnology partners, payors, regulators and prescribers to integrate their unique expertise and perspective. The current global neuroscience portfolio consists of approved medicines which treat adults with major depressive disorder, Alzheimer’s-type dementia, insomnia, multiple sclerosis and Parkinson's disease, and children and adults with attention deficit hyperactivity disorder.In addition, there are many assets in clinical development for targeted patient populations.

About Takeda in the United States

Takeda has maintained a strong and growing commitment to the United States for more than 50 years. On January 8, 2019, Takeda completed its acquisition of Shire, PLC, becoming a global, values-based, R&D-driven biopharmaceutical leader. In the U.S., Takeda employs more than 18,000 employees across multiple business units, and as of August 2019, will be headquartered out of the greater Boston area.

Additionally, Takeda also has a research facility in San Diego, California, specialty products manufacturing facilities in Brooklyn Park, Minnesota, and plasma fractionation manufacturing facilities in Covington, Georgia.

As one of the world’s leading biopharmaceutical companies, Takeda is committed to bringing better health and a brighter future to people worldwide. We aspire to bring our leadership in translating science into life-changing medicines to the next level, in our core focus areas; oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.

Additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.

 

U.S. media contact

Alicia Highlander

Tel: +1-224-554-1426                                              

Email: alicia.highlander@takeda.com

 

[1] National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/major-depression.shtml